Drug eluting stent (DES) in-stent restenosis (ISR) is currently a challenging, seeing as it often requires repeat revascularization. The use of drug coated balloons (DCB) offers the advantage of delivering the drug without the need for re-stenting. This highlights the importance of the technological development of DCB, with diverse drug formulations and coating technologies. As<a href="https://solaci.org/en/2024/07/02/biolimus-vs-paclitaxel-coated-balloons-for-the-treatment-of-in-stent-restenosis/" title="Read more" >...</a>
QFR Analysis of Coronary Lesions with TAVR
While transcatheter aortic valve replacement (TAVR) has shown benefits, significant coronary artery disease affects 50% or more of patients who undergo such procedure. However, it is still unclear which is the best treatment strategy or how to handle this condition. Quantitative flow ratio (QFR) could be a non-invasive option to assess the severity of coronary<a href="https://solaci.org/en/2024/06/29/qfr-analysis-of-coronary-lesions-with-tavr/" title="Read more" >...</a>
Glycemic Control and Coronary Stent Failure
Diabetic patients have twice as high a risk of developing coronary artery disease (CAD). Additionally, CAD increases mortality risk. Patients with a history of percutaneous coronary intervention (PCI) tend to need repeat revascularization, even with second generation stents. To date, there are few studies assessing the role of glycemic control in stent failure, stent thrombosis,<a href="https://solaci.org/en/2024/06/13/glycemic-control-and-coronary-stent-failure/" title="Read more" >...</a>
Coronary Angioplasty with Sirolimus Eluting Stents
At present, most percutaneous coronary intervention procedures (PCI) are done with drug eluting stents (DES). However, drug coated balloons (DCB) have shown benefits in restenosis and small vessel de novo lesions. Intravascular ultrasound (IVUS) has been shown effective in left main PCI and complex procedures, even though there is little infomration on its use for<a href="https://solaci.org/en/2024/06/12/coronary-angioplasty-with-sirolimus-eluting-stents/" title="Read more" >...</a>
Long Term Outcomes of Hyperemic Stenosis Resistance Index (HSR) in Patients with Stable Chronic Angina
The hyperemic stenosis resistance index (HSR) was introduced as a more complete hemodynamic severity indicator of a coronary lesion. HSR combines both pressure drop across a lesion and the flow through it, therefore overcoming the limitations of traditional indices such as fractional flow reserve (FFR) and coronary flow reserve (CFR). The aim of this multicenter<a href="https://solaci.org/en/2024/06/06/long-term-outcomes-of-hyperemic-stenosis-resistance-index-hsr-in-patients-with-stable-chronic-angina/" title="Read more" >...</a>
REPLICA-EPICA 18 Registry: Using IVL in Calcified Coronary Lesions
The presence of calcification in the coronary arteries (CAC) remains the main challenge in the percutaneous treatment of these lesions. Various studies have demonstrated the association of CAC with unfavorable long-term outcomes. Intravascular lithotripsy (IVL) has emerged as an effective tool for fracturing calcified plaques. Studies evaluating this strategy have shown high device success rates,<a href="https://solaci.org/en/2024/05/28/replica-epica-18-registry-using-ivl-in-calcified-coronary-lesions/" title="Read more" >...</a>
Is Intravascular Lithotripsy Equally Effective in All Coronary Calcification Patterns?
Coronary calcifications pose a complex challenge with a high incidence (25% of all angioplasties), thus implying difficult management and adverse long-term outcomes, such as an increased risk of events, especially the need for repeat revascularization. The main mechanisms of long-term failure include stent underexpansion and, in particular, minimal post-deployment stent area. Intravascular lithotripsy (IVL) has<a href="https://solaci.org/en/2024/05/28/is-intravascular-lithotripsy-equally-effective-in-all-coronary-calcification-patterns/" title="Read more" >...</a>
Treatment of Recurrent In-Stent Restenosis with Drug-Eluting Stents: 10-Year Outcomes
In-stent restenosis (ISR) remains the main limitation in the percutaneous treatment of coronary artery disease, with a prevalence between 5% and 10% after implantation of latest-generation drug-eluting stents (DES). Therapeutic recommendations for it include the implantation of a new DES and the use of drug-coated balloons (DCB). The rate of recurrent ISR ranges from 10%<a href="https://solaci.org/en/2024/04/29/treatment-of-recurrent-in-stent-restenosis-with-drug-eluting-stents-10-year-outcomes/" title="Read more" >...</a>
TAVR in the Different Types of Aortic Stenosis
Aortic stenosis (AS) is classified according to gradient into high flow and high gradient (D1), low flow-low gradient with reduced ejection fraction (D2), and paradoxical low flow-low gradient with conserved ejection fraction (D3). D3 AS is characterized by ≥50% ejection fraction, but with systolic volume index ≤35 ml/min. Post TAVR evolution of D2 and D3<a href="https://solaci.org/en/2024/04/05/tavr-in-the-different-types-of-aortic-stenosis/" title="Read more" >...</a>
Physiologically Significant Obstructions in the Left Main Coronary Artery: Revascularizing vs. Deferring
Most randomized studies on revascularization in stable coronary artery disease exclude left main coronary artery disease (LMCAD). One example of this was the ISCHEMIA study. However, the benefits of functional lesion assessment, as demonstrated in the FAME studies, highlight the importance of this tool in guiding decisions regarding revascularization. Nevertheless, the clinical outcomes of patients<a href="https://solaci.org/en/2024/03/27/physiologically-significant-obstructions-in-the-left-main-coronary-artery-revascularizing-vs-deferring/" title="Read more" >...</a>